We are pleased to announce three new additions to our team. They each bring to TIBS extensive scientific and industry experience to strengthen our investment and management capabilities.
Thomas Keller, Ph.D., joined TIBS as Investment Partner on January 1, 2022. Dr. Keller has over 25 years of experience in drug discovery and the set-up of industrial drug discovery research groups. Before TIBS, Dr. Keller served as Head of Chemistry at the Novartis Respiratory Research Center; Head of Chemistry and Deputy Director at the Novartis Institute for Tropical Diseases; Head of Chemistry and Deputy Director at the Experimental Therapeutics Centre and Director of Discovery Chemistry at EDDC. Under his leadership, multiple compounds have been advanced into clinical and commercial stages, such as Cipargamin (Malaria, Phase 2), Indacaterol (Respiratory, marketed) and ETC-159 (Cancer, Phase 1). Dr. Keller earned his Ph.D. in organic chemistry from the University of British Columbia, Canada.
Taoqi Huangfu, Ph.D., joined TIBS as Managing Director on February 1, 2022. Dr. Huangfu’s experience includes biomedical research and development, market authorization and operation management in past two decades. Before TIBS, he served in the Singapore Public Service as Section Head and Deputy Director. Additionally, he is the National Focal Points and Resource Person in various national, regional and international platforms. Prior to his public service roles, Dr. Huangfu worked with various roles in Singapore biotechnology companies like Blueprint Asia and SingVax.
Dr. Huangfu’s credentials include MBBS from Shanghai Second Medical University and Ph.D. in Immunology from the National University of Singapore.
Langdon Wu joined TIBS as General Manager on January 1, 2022. He brings over 20 years of leadership experience in various global companies, which include Thomson Reuters, the LEGO Group, P&G and Accenture. As Vice President at Thomson Reuters, Langdon led global sourcing transformation, mergers and acquisitions as well as divestiture and supply chain ESG. Before joining TIBS, he served as Vice President at the LEGO Group. Langdon is also a professional in contracting, partnership management, commercial management and compliance. He is trained in chemistry and completed an executive MBA program at the National University of Singapore.
Dr. Thomas Keller and Dr. Taoqi Huangfu will oversee existing investment portfolios, identify and valuate new investment opportunities. Langdon Wu will be responsible for overall fund operations.
“I am delighted to welcome Dr. Thomas Keller, Dr. Taoqi Huangfu and Langdon Wu into our firm. Their knowledge and experience will absolutely be a great asset for TIBS. I am very confident that TIBS will achieve even greater success as a Singapore-based biomedical VC with their help,“ said Jack Yin, Founding Partner & Chairman, TIBS
Congratulations to Dr Thomas Keller, Dr Taoqi Huangfu and Langdon Wu. Welcome to TIBS!
